共 50 条
Trial-based cost-effectiveness analysis of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) versus DSAEK
被引:5
|作者:
Simons, Rob W. P.
[1
]
Dickman, Mor M.
[1
]
van den Biggelaar, Frank J. H. M.
[1
]
Dirksen, Carmen D.
[2
]
Van Rooij, Jeroen
[3
]
Remeijer, Lies
[3
]
Van der Lelij, Allegonda
[4
,5
]
Wijdh, Robert H. J.
[6
]
Kruit, Pieter J.
[7
]
Nuijts, Rudy M. M. A.
[1
]
机构:
[1] Maastricht Univ, Med Ctr, Univ Eye Clin Maastricht, POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, CAPHRI Sch Publ Hlth & Primary Care, Dept Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
[3] Rotterdam Eye Hosp, Rotterdam, Netherlands
[4] Univ Med Ctr Utrecht, Dept Ophthalmol, Utrecht, Netherlands
[5] Cent Mil Hosp, Dept Ophthalmol, Utrecht, Netherlands
[6] Univ Med Ctr Groningen, Dept Ophthalmol, Groningen, Netherlands
[7] Euro Tissue Bank, Beverwijk, Netherlands
关键词:
corneal transplantation;
cost-effectiveness;
costs;
Descemet stripping automated endothelial keratoplasty;
Fuchs' endothelial dystrophy;
quality-adjusted life years;
ultrathin Descemet stripping automated endothelial keratoplasty;
POSTERIOR LAMELLAR KERATOPLASTY;
PENETRATING KERATOPLASTY;
OUTCOMES;
D O I:
10.1111/aos.14126
中图分类号:
R77 [眼科学];
学科分类号:
100212 ;
摘要:
Purpose To evaluate the cost-effectiveness of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) versus standard DSAEK. Methods A cost-effectiveness analysis using data from a multicentre randomized clinical trial was performed. The time horizon was 12 months postoperatively. Sixty-four eyes of 64 patients with Fuchs' endothelial dystrophy were included and randomized to UT-DSAEK (n = 33) or DSAEK (n = 31). Relevant resources from healthcare and societal perspectives were included in the cost analysis. Quality-adjusted life years (QALYs) were determined using the Health Utilities Index Mark 3 questionnaire. The main outcome was the incremental cost-effectiveness ratio (ICER; incremental societal costs per QALY). Results Societal costs were euro9431 (US$11 586) for UT-DSAEK and euro9110 (US$11 192) for DSAEK. Quality-adjusted life years (QALYs) were 0.74 in both groups. The ICER indicated inferiority of UT-DSAEK. The cost-effectiveness probability ranged from 37% to 42%, assuming the maximum acceptable ICER ranged from euro2500-euro80 000 (US$3071-US$98 280) per QALY. Additional analyses were performed omitting one UT-DSAEK patient who required a regraft [ICER euro9057 (US$11 127) per QALY, cost-effectiveness probability: 44-62%] and correcting QALYs for an imbalance in baseline utilities [ICER euro23 827 (US$29 271) per QALY, cost-effectiveness probability: 36-59%]. Furthermore, the ICER was euro2101 (US$2581) per patient with clinical improvement in best spectacle-corrected visual acuity (>= 0.2 logMAR) and euro3274 (US$4022) per patient with clinical improvement in National Eye Institute Visual Functioning Questionnaire-25 composite score (>= 10 points). Conclusion The base case analysis favoured DSAEK, since costs of UT-DSAEK were higher while QALYs were comparable. However, additional analyses revealed no preference for UT-DSAEK or DSAEK. Further cost-effectiveness studies are required to reduce uncertainty.
引用
收藏
页码:756 / 763
页数:8
相关论文